Cancer Research Targets Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thøgersen, V. B.
Right arrow Articles by Nexo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thøgersen, V. B.
Right arrow Articles by Nexo, E.
[Cancer Research 61, 6227-6233, August 15, 2001]
© 2001 American Association for Cancer Research

Molecular Biology and Genetics

A Subclass of HER1 Ligands Are Prognostic Markers for Survival in Bladder Cancer Patients1

Vibeke Bech Thøgersen, Boe Sandahl Sørensen, Steen Seier Poulsen, Torben Falck Ørntoft, Hans Wolf and Ebba Nexo2

Departments of Clinical Biochemistry, Aarhus Kommune Hospital [V. B. T., B. S. S., E. N.], Clinical Biochemistry [T. F. Ø.], and Urology, Skejby Sygehus [H. W.], Aarhus University Hospital, DK 8000 Aarhus C, and Department of Anatomy, University of Copenhagen, 2200 Copenhagen [S. S. P.], Denmark

Members of the epidermal growth factor (EGF) family have been suggested as prognostic markers in patients with bladder cancer. Thus far, there has been no consensus on their usefulness. We report an analysis of six ligands and two receptors of which a subset correlate to tumor stage and survival.

Biopsies from bladder cancer tumors were obtained from 73 patients followed for a median of 28 months. The mRNA content for six ligands [EGF, transforming growth factor {alpha} (TGF-{alpha}), amphiregulin (AR), betacellulin (ßCL), heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EPI)] and two receptors [EGF receptor I Human EGF Receptor (HER1) and 2 (HER2)] was examined by a newly developed quantitative reverse transcription-PCR method.

Five ligands and two receptors (HER1 and HER2) were present in median concentrations of (10-21 mol/µg RNA) 0.39 (AR), 11 (ßCL), 2.4 (EPI), 40 (HB-EGF), 1.4 (TGF-{alpha}), 75 (HER1), and 39,000 (HER2). EGF was barely detectable. A significantly higher expression of EPI (P < 0.001), HB-EGF (P < 0.001), and TGF-{alpha} (P < 0.05) were observed in T2-T4 tumors as compared with Ta tumors. Especially the expression of EPI mRNA correlated strongly to survival (P < 0.0005), but increased expression of TGF-{alpha} (P < 0.005), AR, and HB-EGF (P < 0.02) was also associated with a reduced life span.

For the first time, mRNA expression of six ligands and two receptors of the EGF family have been examined in bladder cancer tumors. Our data emphasize that members of the EGF family, especially EPI, may be potential bladder tumor markers.




This article has been cited by other articles:


Home page
 Anticancer ResHome page
F. KOGA, K. KIHARA, and L. NECKERS
Inhibition of Cancer Invasion and Metastasis by Targeting the Molecular Chaperone Heat-shock Protein 90
Anticancer Res, March 1, 2009; 29(3): 797 - 807.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
S. MIYAMOTO, T. FUKAMI, H. YAGI, M. KUROKI, and F. YOTSUMOTO
Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands
Anticancer Res, March 1, 2009; 29(3): 823 - 830.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
T. Kageyama, M. Ohishi, S. Miyamoto, H. Mizushima, R. Iwamoto, and E. Mekada
Diphtheria Toxin Mutant CRM197 Possesses Weak EF2-ADP-ribosyl Activity that Potentiates its Anti-tumorigenic Activity
J. Biochem., July 1, 2007; 142(1): 95 - 104.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
S. Matsui, M. Ito, H. Nishiyama, H. Uno, H. Kotani, J. Watanabe, P. Guilford, A. Reeve, M. Fukushima, and O. Ogawa
Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models
Bioinformatics, March 15, 2007; 23(6): 732 - 738.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
N. Yamamoto, G. Mammadova, R. X.-D. Song, Y. Fukami, and K.-i. Sato
Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells
J. Cell Sci., November 15, 2006; 119(22): 4623 - 4633.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. H. Dickson, A. Grabowska, M. El-Zaatari, J. Atherton, and S. A. Watson
Helicobacter pylori Can Induce Heparin-Binding Epidermal Growth Factor Expression via Gastrin and Its Receptor.
Cancer Res., August 1, 2006; 66(15): 7524 - 7531.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Tanaka, S. Miyamoto, S. O. Suzuki, E. Oki, H. Yagi, K. Sonoda, A. Yamazaki, H. Mizushima, Y. Maehara, E. Mekada, et al.
Clinical Significance of Heparin-Binding Epidermal Growth Factor-Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4783 - 4792.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. Lee, R. S. Pearsall, S. Das, S. K. Dey, V. L. Godfrey, and D. W. Threadgill
Epiregulin Is Not Essential for Development of Intestinal Tumors but Is Required for Protection from Intestinal Damage
Mol. Cell. Biol., October 15, 2004; 24(20): 8907 - 8916.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. P. Ongusaha, J. C. Kwak, A. J. Zwible, S. Macip, S. Higashiyama, N. Taniguchi, L. Fang, and S. W. Lee
HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis
Cancer Res., August 1, 2004; 64(15): 5283 - 5290.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. B. Mehta and G. E. Besner
Inhibition of NF-{kappa}B Activation and Its Target Genes by Heparin-Binding Epidermal Growth Factor-Like Growth Factor
J. Immunol., December 1, 2003; 171(11): 6014 - 6022.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. M. Grana, C. I. Sartor, and A. D. Cox
Epidermal Growth Factor Receptor Autocrine Signaling in RIE-1 Cells Transformed by the Ras Oncogene Enhances Radiation Resistance
Cancer Res., November 15, 2003; 63(22): 7807 - 7814.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Lindvall, M. Hou, T. Komurasaki, C. Zheng, M. Henriksson, J. M. Sedivy, M. Bjorkholm, B. T. Teh, M. Nordenskjold, and D. Xu
Molecular Characterization of Human Telomerase Reverse Transcriptase-immortalized Human Fibroblasts by Gene Expression Profiling: Activation of the Epiregulin Gene
Cancer Res., April 15, 2003; 63(8): 1743 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. M. Adam, T. Danciu, D. L. McLellan, J. G. Borer, J. Lin, D. Zurakowski, M. H. Weinstein, P. H. Rajjayabun, J. K. Mellon, and M. R. Freeman
A Nuclear Form of the Heparin-binding Epidermal Growth Factor-like Growth Factor Precursor Is a Feature of Aggressive Transitional Cell Carcinoma
Cancer Res., January 15, 2003; 63(2): 484 - 490.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.